<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Celltrion, Inc. — News on 6ix</title>
<link>https://6ix.com/company/celltrion-inc</link>
<description>Latest news and press releases for Celltrion, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/celltrion-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68362c5878dffbe2df146009.webp</url>
<title>Celltrion, Inc.</title>
<link>https://6ix.com/company/celltrion-inc</link>
</image>
<item>
<title>Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrion-to-present-seven-abstracts-in-inflammatory-bowel-disease-ibd-at-2026-digestive-disease-weekr-ddw</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrion-to-present-seven-abstracts-in-inflammatory-bowel-disease-ibd-at-2026-digestive-disease-weekr-ddw</guid>
<pubDate>Tue, 21 Apr 2026 12:00:00 GMT</pubDate>
<description>Celltrion, Inc. today announced that seven abstracts will be presented at the 2026 Digestive Disease Week® (DDW) Annual Meeting, taking place May 2-5 in Chicago, Illinois. The oral and poster presentations will feature data including post-hoc analysis of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA®, the first and only FDA-approved subcutaneous infliximab.</description>
</item>
<item>
<title>Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrion-announces-us-availability-of-avtozmar-tocilizumab-anoh-subcutaneous-sc-formulation</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrion-announces-us-availability-of-avtozmar-tocilizumab-anoh-subcutaneous-sc-formulation</guid>
<pubDate>Mon, 16 Mar 2026 12:00:00 GMT</pubDate>
<description>Celltrion, Inc. today announced that AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation is now commercially available to patients in the United States.</description>
</item>
<item>
<title>Zymfentra (Celltrion) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/celltrion-inc/news/zymfentra-celltrion-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/zymfentra-celltrion-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Fri, 13 Mar 2026 11:53:00 GMT</pubDate>
<description>Opportunities in the Zymfentra market include advancements in enzyme therapies, boosted by regulatory approvals, rising R&D investments, improved homecare models, and a growing focus on rare genetic disorders and aging populations. Challenges include tariffs affecting costs, driving localized production.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Zymfentra Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. Th</description>
</item>
<item>
<title>Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrion-presents-innovative-drug-pipeline-011800131</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrion-presents-innovative-drug-pipeline-011800131</guid>
<pubDate>Wed, 14 Jan 2026 01:18:00 GMT</pubDate>
<description>Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today presented key strategic priorities and clinical development updates for its innovative drug pipelines including antibody-drug conjugates (ADCs) and multi-specific antibodies (msAbs) at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The company also highlighted plans to expand its manufacturing and R&D capabilities to support long-term growth, enhance supply resilience and reinforce its</description>
</item>
<item>
<title>Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrion-present-44th-annual-j-234200982</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrion-present-44th-annual-j-234200982</guid>
<pubDate>Tue, 06 Jan 2026 23:42:00 GMT</pubDate>
<description>Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced that Jin-Seok Seo, Chief Executive Officer and Hyuk-Jae Lee, Senior Executive Vice President at Celltrion, will present at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California on January 12–15, 2026.</description>
</item>
<item>
<title>Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrion-announces-u-fda-approval-004300123</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrion-announces-u-fda-approval-004300123</guid>
<pubDate>Wed, 03 Dec 2025 00:43:00 GMT</pubDate>
<description>Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg/2mL solution in a single-dose prefilled syringe for subcutaneous injection. In the U.S., OMLYCLO will be marketed and distributed exclusively by Celltrion USA, Inc.</description>
</item>
<item>
<title>Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrion-announces-publication-post-hoc-064800088</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrion-announces-publication-post-hoc-064800088</guid>
<pubDate>Wed, 26 Nov 2025 06:48:00 GMT</pubDate>
<description>Celltrion, Inc. today announced that a post-hoc analysis of the LIBERTY-CD study, which showed that the efficacy of ZYMFENTRA® (infliximab-dyyb) is consistent regardless of disease location, has been published in a peer reviewed journal, Clinical Gastroenterology and Hepatology.[1]</description>
</item>
<item>
<title>Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases</title>
<link>https://6ix.com/company/celltrion-inc/news/kaigene-enters-into-exclusive-licensing-agreement-with-celltrion-for-novel-antibody-therapeutics-in-autoimmune-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/kaigene-enters-into-exclusive-licensing-agreement-with-celltrion-for-novel-antibody-therapeutics-in-autoimmune-diseases</guid>
<pubDate>Tue, 04 Nov 2025 00:00:00 GMT</pubDate>
<description>Kaigene Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced today that it has entered into an exclusive global licensing agreement with Celltrion Inc., a leading global biopharmaceutical company, for two of Kaigene's nonclinical-stage assets, KG006 and KG002.</description>
</item>
<item>
<title>U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)</title>
<link>https://6ix.com/company/celltrion-inc/news/u-fda-grants-interchangeability-designation-072800410</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/u-fda-grants-interchangeability-designation-072800410</guid>
<pubDate>Thu, 30 Oct 2025 07:28:00 GMT</pubDate>
<description>Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable biosimilars to the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications.</description>
</item>
<item>
<title>FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States</title>
<link>https://6ix.com/company/celltrion-inc/news/fda-approves-expanded-pediatric-indications-053200180</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/fda-approves-expanded-pediatric-indications-053200180</guid>
<pubDate>Fri, 17 Oct 2025 05:32:00 GMT</pubDate>
<description>Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved expanded indications for YUFLYMA® (adalimumab-aaty) and its unbranded version, to include the treatment of hidradenitis suppurativa (HS) in adolescent patients aged 12 years and older, and uveitis (UV) in pediatric patients aged 2 years and older.[1],[2]</description>
</item>
<item>
<title>Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrion-receives-u-fda-approval-225600889</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrion-receives-u-fda-approval-225600889</guid>
<pubDate>Thu, 09 Oct 2025 22:56:00 GMT</pubDate>
<description>Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept), for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR).[1]</description>
</item>
<item>
<title>Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrion-launches-avtozma-tocilizumab-anoh-123000689</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrion-launches-avtozma-tocilizumab-anoh-123000689</guid>
<pubDate>Thu, 02 Oct 2025 12:30:00 GMT</pubDate>
<description>Celltrion, Inc. today announced that AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation is now available to patients in the United States.</description>
</item>
<item>
<title>FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)</title>
<link>https://6ix.com/company/celltrion-inc/news/fda-approves-expanded-indication-avtozma-120000757</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/fda-approves-expanded-indication-avtozma-120000757</guid>
<pubDate>Wed, 06 Aug 2025 12:00:00 GMT</pubDate>
<description>Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of AVTOZMA® (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older. Following FDA approval of the additional indication for CRS, AVTOZMA IV now aligns with all indications approved for ACTEMRA® IV in the United States.[1]</description>
</item>
<item>
<title>Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrion-usa-announces-u-launch-020800044</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrion-usa-announces-u-launch-020800044</guid>
<pubDate>Tue, 08 Jul 2025 02:08:00 GMT</pubDate>
<description>Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively, are commercially available in the United States.</description>
</item>
<item>
<title>Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrion-announces-u-fda-approval-233000068</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrion-announces-u-fda-approval-233000068</guid>
<pubDate>Sun, 15 Jun 2025 23:30:00 GMT</pubDate>
<description>Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection. The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years, weighing less than 60kg, with plaque psoriasis (PsO) or psoriatic arthritis (PsA).[1] With this approval, STEQEYMA now offers all dosage fo</description>
</item>
<item>
<title>Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrions-yuflyma-adalimumab-aaty-receives-174700401</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrions-yuflyma-adalimumab-aaty-receives-174700401</guid>
<pubDate>Fri, 23 May 2025 17:47:00 GMT</pubDate>
<description>Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA® (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) presentations. With this approval, YUFLYMA is now fully interchangeable with the reference product, Humira® (adalimumab), across all marketed dosage forms and strengths.</description>
</item>
<item>
<title>Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrion-present-six-abstracts-inflammatory-120000924</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrion-present-six-abstracts-inflammatory-120000924</guid>
<pubDate>Mon, 28 Apr 2025 12:00:00 GMT</pubDate>
<description>Celltrion, Inc. today announced that six abstracts will be presented at the 2025 Digestive Disease Week® (DDW) Annual Meeting, taking place May 3-6 in San Diego, California. The oral and poster presentations will feature data including post hoc analyses of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA®, the first and only FDA-approved subcutaneous infliximab.</description>
</item>
<item>
<title>Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program</title>
<link>https://6ix.com/company/celltrion-inc/news/celltrions-steqeyma-ustekinumab-stba-now-052900404</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/celltrions-steqeyma-ustekinumab-stba-now-052900404</guid>
<pubDate>Thu, 27 Mar 2025 05:29:00 GMT</pubDate>
<description>Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to the Costco Member Prescription Program.</description>
</item>
<item>
<title>STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States</title>
<link>https://6ix.com/company/celltrion-inc/news/steqeyma-ustekinumab-stba-biosimilar-stelara-233000013</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/steqeyma-ustekinumab-stba-biosimilar-stelara-233000013</guid>
<pubDate>Wed, 12 Mar 2025 23:30:00 GMT</pubDate>
<description>Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024. STEQEYMA is approved for the same indications as STELARA, providing consistency in treatment for patients and healthcare providers.[1]</description>
</item>
<item>
<title>U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®</title>
<link>https://6ix.com/company/celltrion-inc/news/u-fda-approves-celltrions-omlyclo-231600450</link>
<guid isPermaLink="true">https://6ix.com/company/celltrion-inc/news/u-fda-approves-celltrions-omlyclo-231600450</guid>
<pubDate>Sun, 09 Mar 2025 23:16:00 GMT</pubDate>
<description>Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), Immunoglobulin E (IgE)-mediated food allergy, and chronic spontaneous urticaria (CSU).[2]</description>
</item>
</channel>
</rss>